BioStar Capital is a value-add investment firm focused on transformational medical device technologies in cardiovascular and orthopaedic medicine. Combining the insight of experienced investment professionals and world-renowned medical thought leaders, BioStar Capital identifies proprietary technologies that serve unmet patient needs and fit the acquisition criteria of leading medical device companies. BioStar Capital fills an important gap in medical device innovation and provides operational skills and clinical expertise in addition to capital, enabling the firm to actively mitigate risk, optimize product development, and secure successful exit. The firm has invested in over 30 med-tech companies, many of which have been acquired by a major medical device manufacturer.

BioStar News
Portfolio News
1/4

July 14, 2019

BioStar Capital Expands VC Fund to $91 Million

>> Read More

October 10, 2016

Professor Ian Meredith, Cardiovascular Medical Venture Partner for BioStar, To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer

>> Read More

March 22, 2020

Olympic Ophthalmics Presents Clinical Evidence for iTEAR100®

>> Read More

May 14, 2020

Olympic Ophthalmics Receives FDA Clearance for iTEAR100® Neurostimulator

>> Read More

Active Portfolio Companies
ASI Logo - New.png
cathworks_logo-01.jpg
NewPace
Trice Logo - New.png
V-Wave